Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 21

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 21
---
 The decrease of Other Components of Equity ( JPY -157.4 billion) was mainly due to currency translation adjustments reflecting the depreciation of the Japanese yen.

<div align='center'>10</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

(3) Consolidated Cash Flows

|                                                               |     | Billion JPY                         
 For the fiscal year ended March 31, |   2024 |     |     |    2025 |     |     | Change |
|:--------------------------------------------------------------|:----|:------------------------------------|-------:|:----|:----|--------:|:----|:----|-------:|
| Net cash from operating activities                            |     |                                     |  716.3 |     |     | 1,057.2 |     |     |  340.8 |
| Net cash used in investing activities                         |     |                                     | -463.9 |     |     |  -367.1 |     |     |   96.8 |
| Net cash used in financing activities                         |     |                                     | -354.4 |     |     |  -751.4 |     |     | -397.0 |
| Net decrease in cash and cash equivalents                     |     |                                     | -101.9 |     |     |   -61.3 |     |     |   40.6 |
| Cash and cash equivalents at the beginning of the year        |     |                                     |  533.5 |     |     |   457.8 |     |     |  -75.7 |
| Effects of exchange rate changes on cash and cash equivalents |     |                                     |   26.2 |     |     |   -11.4 |     |     |  -37.6 |
| Cash and cash equivalents at the end of the year              |     |                                     |  457.8 |     |     |   385.1 |     |     |  -72.7 |

#### Net Cash from Operating Activities
Net Cash from Operating Activities was JPY 1,057.2 billion ( JPY +340.8 billion ). The increase was mainly due to favorable impacts from Changes in Assets and Liabilities driven by changes in Provisions and Inventories, partially offset by a lower net profit for the year adjusted for non-cash